CAPRICOR THERAPEUTICS, INC. (CAPR) 8-K Current Report: March 10, 2026
Filed: March 10, 2026
Health Care
Pharmaceutical PreparationsCAPRICOR THERAPEUTICS, INC. (CAPR) 8-K current report filed with SEC EDGAR on March 10, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 7.01: Regulation FD Disclosure
- Item 8.01: Other Events
CAPRICOR THERAPEUTICS, INC. 8-K Mar 10, 2026 Event Analysis
Item 7.01 · Regulation FD Disclosure
- • FDA lifted prior Complete Response Letter (CRL) and resumed BLA review for Deramiocel in Duchenne muscular dystrophy cardiomyopathy — major regulatory hurdle cleared
- • CRL removal signals FDA's prior objections addressed, meaningfully raising probability of full approval
- • Deramiocel targets DMD cardiomyopathy, a rare/orphan indication with no approved cell therapies — significant market opportunity if approved
Item 8.01 · Other Events
- • FDA lifted CRL and resumed BLA review for Deramiocel (cell therapy for DMD cardiomyopathy) — major regulatory reversal removing a key overhang
- • Classified as Class 2 resubmission with PDUFA action date of August 22, 2026 — sets clear approval timeline for investors
- • Company flagged potential eligibility for a Priority Review Voucher (PRV) — PRVs have sold for $100M+ historically, representing significant non-dilutive upside
Other CAPRICOR THERAPEUTICS, INC. 8-K Filings
Get deeper insights on CAPRICOR THERAPEUTICS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.